In silico discovery of nanobody binders to a G-protein coupled receptor using AlphaFold-Multimer
Authors:
- Edward P. HarveyEHEdward P. Harvey
- Jeffrey S. SmithJSJeffrey S. Smith
- Joseph D. HurleyJHJoseph D. Hurley
- Alyana GranadosAGAlyana Granados
- Ernst W. SchmidESErnst W. Schmid
- Jason G. Liang-LinJLJason G. Liang-Lin
- Steffanie PaulSPSteffanie Paul
- Emily M. MearaEMEmily M. Meara
- Matthew P. FergusonMFMatthew P. Ferguson
- Victor G. Calvillo-MirandaVCVictor G. Calvillo-Miranda
- Debora S. MarksDMDebora S. Marks
- Johannes C. WalterJWJohannes C. Walter
Preprint
Abstract
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.Keywords
All Related Versions
- Published version: Nature Communications, 17.
This publication has 42 references indexed in Scilit:
- Phosphorylation barcodes direct biased chemokine signaling at CXCR3Cell Chemical Biology, 2023
- The structure, function, and pharmacology of MRGPRsTrends in Pharmacological Sciences, 2023
- MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugsPharmacology & Therapeutics, 2022
- Designing antibodies as therapeuticsCell, 2022
- MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous UrticariaJournal of Investigative Dermatology, 2021
- Nanobody approval gives domain antibodies a boostNature Reviews Drug Discovery, 2019
- A single amino acid in MRGPRX2 necessary for binding and activation by pruritogensJournal of Allergy and Clinical Immunology, 2017
- Measuring Mast Cell Mediator ReleaseCurrent Protocols in Immunology, 2010
- Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptorsBiochemical and Biophysical Research Communications, 2006
- Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc ComplexMolecular Cell, 2001